Blog

- Uncategorized

Clinical Trial Demonstrates Accurate Non-Invasive Detection of In Vivo Biologic Activity in Melanomas by the Orlucent® Skin Fluorescent Imaging System

LOS GATOS, Calif., Jan. 20, 2026 /PRNewswire/ — In the pivotal clinical trial of their technology, researchers at Orlucent®, Inc. have confirmed the accuracy of the company’s Skin Fluorescent Imaging (SFI) System, a non-invasive, hand-held molecular imaging device for the direct, on-the-skin, point-of-care assessment of suspicious moles and early detection of melanoma-related activity.

Read More »